Mavacamten is an orally active cardiac myosin inhibitor used in the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (HCM). It selectively and reversibly reduces excessive cardiac myosin activity, helping decrease hypercontractility and improve cardiac function.
Mavacamten is a small-molecule pharmaceutical API and is marketed as an oral capsule.
Mavacamten is a specialized cardiovascular pharmaceutical API used in the development and manufacture of medicines for hypertrophic cardiomyopathy.
Key quality attributes include identity, assay, related substances, residual solvents, water content, elemental impurities, stereochemical purity and stability characteristics.
CAS Number: 1642288-47-8
Molecular Formula: C15H19N3O2
Molecular Weight: 273.33 g/mol
Chemical Name: Mavacamten
Development Code: MYK-461
Drug Class: Cardiac Myosin Inhibitor
Therapeutic Class: Cardiovascular Agent
Therapeutic Area: Cardiology
Molecule Type: Synthetic Small Molecule
Mavacamten is a selective, allosteric and reversible inhibitor of cardiac myosin ATPase.
It reduces the number of cardiac myosin heads available for interaction with actin, thereby decreasing excessive actin-myosin cross-bridge formation.
Its pharmacological effects include:
Mavacamten API is used in pharmaceutical development for:
Mavacamten is primarily associated with obstructive hypertrophic cardiomyopathy, a condition characterized by excessive thickening of the heart muscle and, in some patients, obstruction of blood flow from the left ventricle.
By reducing excessive cardiac contractility, mavacamten can reduce left ventricular outflow tract obstruction and improve symptoms in appropriately selected patients.
Mavacamten is developed as an oral capsule.
Available capsule strengths include:
Mavacamten is a synthetic small-molecule compound. Its physical and chemical characteristics should be controlled according to the applicable API specification, including purity, stereochemical composition and solid-state properties.
A controlled Mavacamten API manufacturing process may involve:
Typical Mavacamten API testing may include:
Store Mavacamten API in a tightly closed container under controlled pharmaceutical storage conditions, protected from excessive heat, moisture and direct light. Final storage conditions should follow the manufacturer's validated stability data.
Mavacamten is relevant to research involving:
Mavacamten is an oral cardiac myosin inhibitor with CAS Number 1642288-47-8, molecular formula C15H19N3O2, and molecular weight 273.33 g/mol. It reduces excessive cardiac myosin activity and is primarily used for adults with symptomatic obstructive hypertrophic cardiomyopathy.
| Parameter | Specification |
|---|---|
| Appearance | White to off-white crystalline powder |
| Identification | IR & HPLC compliant |
| Assay (HPLC) | 98.0% – 102.0% |
| Loss on Drying | NMT 2.0% |
| Residue on Ignition | NMT 0.5% |
| Heavy Metals | NMT 10 ppm |
| pH (1% Solution) | 4.0 – 6.0 |
| Individual Impurity | NMT 0.5% |
| Total Impurities | NMT 1.0% |
| Water Content | NMT 2.0% |